Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease
Top Cited Papers
- 1 April 2002
- journal article
- clinical trial
- Published by Springer Nature in Neurological Sciences
- Vol. 23 (1) , 41-43
- https://doi.org/10.1007/s100720200022
Abstract
As cholinergic mechanisms may be at least partially responsible for hallucinations and delusions in Parkinson's disease (PD), we conducted an open study in 8 PD patients to assess the efficacy and tolerability of the cholinesterase inhibitor donepezil, 5 mg at bedtime for two months, in the treatment of these complications. Hallucinations and delusions improved significantly in all patients. Donezepil was overall well tolerated, but a deterioration in motor disability was noted in 2 out of 8 patients.Keywords
This publication has 0 references indexed in Scilit: